Biodesix (BDSX) vs Castle Biosciences (CSTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Biodesix (BDSX) has outperformed Castle Biosciences (CSTL) over the past year, gaining 261.9% versus a gain of 44.0%. Over five years, CSTL leads with a -48.1% price change compared with -82.4% for BDSX. Castle Biosciences is the larger company by market cap ($1.01 billion vs $278.8 million), about 3.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDSX | CSTL |
|---|---|---|
| Share price | $26.42 | $33.00 |
| Market cap | $278.76M | $1.01B |
| 1-day change | -5.51% | -1.08% |
| YTD return | +288.53% | -15.17% |
| 1-year return | +261.92% | +43.98% |
| 5-year return | -82.39% | -48.10% |
| EPS (TTM) | $-3.10 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.97 | $44.28 |
| 52-week low | $5.26 | $17.72 |
| Distance from 52-week high | -17.36% | -25.47% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +41.29% | +36.70% |
| Average volume | 101.54K | 401.95K |
| Shares outstanding | 10.55M | 30.55M |
| Employees | 334 | 1,002 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Castle Biosciences is about 3.6 times larger than Biodesix by market value ($1.01B vs $278.76M).
- BDSX has outperformed CSTL by 217.9 percentage points over the past year.
About Biodesix
BDSX stock →Biodesix, Inc. operates as a diagnostic solutions company.
Healthcare · Diagnostics & Research · 334 employees
About Castle Biosciences
CSTL stock →Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions.
Healthcare · Diagnostics & Research · 1,002 employees
BDSX vs CSTL FAQ
Which is bigger, Biodesix or Castle Biosciences?
Castle Biosciences (CSTL) is larger, with a market capitalization of $1.01B compared with $278.76M for Biodesix (BDSX).
Which stock has performed better over the past year, BDSX or CSTL?
BDSX returned +261.92% over the past 12 months, compared with +43.98% for CSTL (price return, excluding dividends). Past performance does not predict future results.
Are Biodesix and Castle Biosciences in the same industry?
Yes. Both are classified in the Diagnostics & Research industry within the Healthcare sector.